目的测定国人全身麻醉下瑞芬太尼的药物代谢动力学参数,并与既往国外文献进行比较.方法择期手术成年患者10例,在全麻诱导后静脉单次注射瑞芬太尼5 - 6 μg·kg-1,随后在注射后0、1、2、3、5、7、10、15、20、25、30、45、60及90分钟抽取动脉血.采用液质联用测定法 (HPLC/MS/MS) 测定瑞芬太尼血药浓度.结果瑞芬太尼血药浓度-时间曲线变化符合二房室模型.平均分布半衰期 (t1/2 α)为1.56 min (0.73 ～ 2.31),消除半衰期 (t1/2β)为 22.07 min (9. 71 ～ 36.07),清除率为 (CL) 2.149 L·min-1 (1.370 ～ 2.629),表观分布容积(Vd)为 65.766 L (23.069 ～ 108.379).结论国人瑞芬太尼的药代动力学参数中表观分布容积明显大于国外研究结果,提示不同种族群体间的药代动力学变化存在差异.%Aim To study the pharmacokinetics of remifentanil in Chinese adult patients undergoing elective surgery and compare the results with the data already published. Methods The pharmacokinetics of remifentanil was determined in 10 adult patients undergoing elective surgery. Remifentanil 5 - 6 μg·kg-1 was administered within 1 min after the induction of anesthesia. One point five millilitre of arterial blood samples were collected at 0 (baseline), 1, 2, 3, 5, 7, 10, 15, 20, 25, 30, 45, 60, and 90 min after drug administration. Remifentanil concentration was assayed by HPLC/MS/MS. Results The concentration-time course of remifentanil was best described by a two-compartment model. Total clearance (CL = 2.149 ± 0.431 L·min-1) of remifentanil was greater than the normal hepatic blood flow. The distribution half-life (t1/2 α) [1.56 ± 0.52 min (0.73 - 2.31)] and the elimination half-life (t1/2 β) [22.07 ± 10.30 min (9.71-36.07)] were similar with those in previous reports. Volume of distribution (Vd = 65.766 ± 29.100 L) was about two times greater than that reported in previous studies of other ethnics. Conclusion In the present study, the volume of distribution is significantly greater than that reported in previous studies of other ethnics, indicating that there are some differences in the pharmacokinetics of remifentanil among different ethnics.
展开▼
